scispace - formally typeset
J

Judith P. Kelly

Researcher at Boston University

Publications -  70
Citations -  8243

Judith P. Kelly is an academic researcher from Boston University. The author has contributed to research in topics: Population & Risk factor. The author has an hindex of 36, co-authored 70 publications receiving 7910 citations. Previous affiliations of Judith P. Kelly include Seattle Children's.

Papers
More filters
Journal ArticleDOI

Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States: The Slone Survey

TL;DR: In any given week, most US adults take at least 1 medication, and many take multiple agents; the substantial overlap between use of prescription medications and herbals/supplements raises concern about unintended interactions.
Journal ArticleDOI

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

TL;DR: Risks were increased for trimethoprim–sulfamethoxazole and other sulfonamide antibiotics, chlormezanone, quinolones, and aminopenicillins among drugs usually used for short periods.
Journal ArticleDOI

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

TL;DR: The use of antibacterial sulfonamides, anticonvulsant agents, oxicam NSAIDs, allopurinol, chlormezanone, and corticosteroids is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, but for none of the drugs does the excess risk exceed five cases per million users per week.
Journal ArticleDOI

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product

TL;DR: Use of low doses of enteric-coated or buffered aspirin carries a three-fold increase in the risk of major UGIB, suggesting the assumption that these formulations are less harmful than plain aspirin may be mistaken.
Journal ArticleDOI

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.

TL;DR: SJS and TEN are associated with short-term therapy with phenytoin, phenobarbital, and carbamazepine, and the association with valproic acid seems to be confounded by concomitant short- term therapy with other causal drugs.